Kevin Albuquerque1, Brian A Hrycushko2, Matthew M Harkenrider3, Jyoti Mayadev4, Ann Klopp5, Sushil Beriwal6, Daniel G Petereit7, Daniel J Scanderbeg4, Catherine Yashar4. 1. Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX. Electronic address: kevin.albuquerque@utsouthwestern.edu. 2. Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX. 3. Department of Radiation Oncology, Loyola University, Chicago, IL. 4. Department of Radiation Medicine and Applied Sciences, UC San Diego, La Jolla, CA. 5. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX. 6. Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA. 7. Rapid City Regional Hospital, Rapid City, SD.
Abstract
PURPOSE: The purpose of this study was to report a list of accepted fractionation schemes for high-dose-rate (HDR) brachytherapy for gynecological cancers in a definitive, neoadjuvant, or adjuvant setting. METHODS AND MATERIALS: Members of the American Brachytherapy Society (ABS) Task Force with expertise in gynecological brachytherapy reviewed the literature and existing ABS guidelines regarding various dose-fractionation schedules for HDR brachytherapy to create this compendium. Other resources include current guidelines published by medical societies, clinical trials, the published medical literature, and the clinical experience of the ABS Task Force members. The ABS consensus statements for HDR brachytherapy practice were reviewed for these fractionation schemes and form the major source for this report. Specific recommendations for therapy and recommendations for further investigations were made when there was agreement. RESULTS: A variety of dose-fractionation schedules for HDR brachytherapy alone or integrating brachytherapy with external-beam radiation exist. The choice of a given fractionation schedule may be appropriate depending on the practice situation for the patient and the resources available. While there is no single optimal dose-fractionation scheme for any disease site or clinical situation, higher doses per fraction with fewer fractions per regimen have been known to increase toxicity. The corresponding 2-Gray (Gy) per fraction radiobiologic equivalent doses have been provided (normalized therapy dose) to compare the various regimens where indicated and can be used to estimate isoeffective schedules. CONCLUSIONS: This compendium of HDR brachytherapy fractionation schedules provides various options to the gynecologic brachytherapist and a ready reference for clinical use in the management of gynecological cancer treatments.
PURPOSE: The purpose of this study was to report a list of accepted fractionation schemes for high-dose-rate (HDR) brachytherapy for gynecological cancers in a definitive, neoadjuvant, or adjuvant setting. METHODS AND MATERIALS: Members of the American Brachytherapy Society (ABS) Task Force with expertise in gynecological brachytherapy reviewed the literature and existing ABS guidelines regarding various dose-fractionation schedules for HDR brachytherapy to create this compendium. Other resources include current guidelines published by medical societies, clinical trials, the published medical literature, and the clinical experience of the ABS Task Force members. The ABS consensus statements for HDR brachytherapy practice were reviewed for these fractionation schemes and form the major source for this report. Specific recommendations for therapy and recommendations for further investigations were made when there was agreement. RESULTS: A variety of dose-fractionation schedules for HDR brachytherapy alone or integrating brachytherapy with external-beam radiation exist. The choice of a given fractionation schedule may be appropriate depending on the practice situation for the patient and the resources available. While there is no single optimal dose-fractionation scheme for any disease site or clinical situation, higher doses per fraction with fewer fractions per regimen have been known to increase toxicity. The corresponding 2-Gray (Gy) per fraction radiobiologic equivalent doses have been provided (normalized therapy dose) to compare the various regimens where indicated and can be used to estimate isoeffective schedules. CONCLUSIONS: This compendium of HDR brachytherapy fractionation schedules provides various options to the gynecologic brachytherapist and a ready reference for clinical use in the management of gynecological cancer treatments.
Authors: Giuseppe Facondo; Gianluca Vullo; Vitaliana DE Sanctis; Maurizio Valeriani; Anna Maria Ascolese; Maria Massaro; Dimitri Anzellini; Mattia Falchetto Osti Journal: Cancer Diagn Progn Date: 2021-05-03
Authors: Vonetta M Williams; Jenna M Kahn; Matthew M Harkenrider; Junzo Chino; Jonathan Chen; L Christine Fang; Emily F Dunn; Emma Fields; Jyoti S Mayadev; Ramesh Rengan; Daniel Petereit; Brandon A Dyer Journal: Brachytherapy Date: 2020-04-21 Impact factor: 2.362
Authors: Vonetta M Williams; Jenna M Kahn; Nikhil G Thaker; Sushil Beriwal; Paul L Nguyen; Douglas Arthur; Daniel Petereit; Brandon A Dyer Journal: Adv Radiat Oncol Date: 2020-11-06
Authors: Garrett L Jensen; Parul N Barry; Harriet Eldredge-Hindy; Scott R Silva; Sarah L Todd; Kendall P Hammonds; Walker R Zimmerman; Daniel S Metzinger; Moataz N El-Ghamry Journal: J Contemp Brachytherapy Date: 2021-05-07
Authors: Vitaliana De Sanctis; Daniela Musio; Francesca De Felice; Francesco Marampon; Maurizio Valeriani; Paolo Bonome; Dimitri Anzellini; Giuseppe Facondo; Gianluca Vullo; Maria Massaro; Mario Di Staso; Pierluigi Bonfili; Agnieszka Chalaszczyk; Giovanni Luca Gravina; Vincenzo Tombolini; Mattia Falchetto Osti Journal: J Contemp Brachytherapy Date: 2020-04-30